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Vascular Pathophysiology in
Response to Increased Heart Rate
Florian Custodis, MD,* Stephan H. Schirmer, MD, PHD,* Magnus Baumhäkel, MD,*
Gerd Heusch, MD,† Michael Böhm, MD,* Ulrich Laufs, MD*
Homburg/Saar and Essen, Germany
This review summarizes the current literature and the open questions regarding the physiology and pathophysiol-
ogy of the mechanical effects of heart rate on the vessel wall and the associated molecular signaling that may
have implications for patient care. Epidemiological evidence shows that resting heart rate is associated with car-
diovascular morbidity and mortality in the general population and in patients with cardiovascular disease. As a
consequence, increased resting heart rate has emerged as an independent risk factor both in primary prevention
and in patients with hypertension, coronary artery disease, and myocardial infarction. Experimental and clinical
data suggest that sustained elevation of heart rate—independent of the underlying trigger—contributes to the
pathogenesis of vascular disease. In animal studies, accelerated heart rate is associated with cellular signaling
events leading to vascular oxidative stress, endothelial dysfunction, and acceleration of atherogenesis. The un-
derlying mechanisms are only partially understood and appear to involve alterations of mechanic properties
such as reduction of vascular compliance. Clinical studies reported a positive correlation between increased rest-
ing heart rate and circulating markers of inflammation. In patients with coronary heart disease, increased rest-
ing heart rate may influence the clinical course of atherosclerotic disease by facilitation of plaque disruption and
progression of coronary atherosclerosis. While a benefit of pharmacological or interventional heart rate reduc-
tion on different vascular outcomes was observed in experimental studies, prospective clinical data are limited,
and prospective evidence determining whether modulation of heart rate can reduce cardiovascular events in
different patient populations is needed. (J Am Coll Cardiol 2010;56:1973–83) © 2010 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.09.014(
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cesting heart rate is an easily accessible clinical parameter.
rom vascular risk factors to endothelial function, coronary
lood flow to atherosclerotic plaque development, plaque
upture, and myocardial infarction, heart rate affects several
tages of the cardiovascular disease continuum (1–5). The
nitiation of the heart beat by spontaneous sinoatrial node
epolarization is determined by voltage-sensitive membrane
urrents, particularly the hyperpolarization-activated pace-
aker current I(f), and by calcium release from the sarco-
lasmic reticulum, leading to diastolic depolarization
hrough activation of the sodium-calcium exchanger cur-
ent. The I(f) current was first described almost 30 years ago
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ccepted September 15, 2010.6); f stands for “funny” because of the unusual properties of
(f) relative to other systems known at the time. These
roperties comprise mixed permeability to sodium and
otassium ions, activation by hyperpolarization, and slow
ctivation and deactivation kinetics (7). The sinoatrial node
esponds to physical and mental activity or sleep states
hrough the autonomic nervous system and circulating
ormones, which integrate notably cardiorespiratory and
aroreceptor, but also more complex inputs such as emo-
ion, exercise, and stress (for review, see DiFrancesco [7]
nd Verrier and Tan [8]). Therefore, increased heart rate
eflects increased sympathetic and/or decreased vagal tone
nd, indirectly, life-style such as psychosocial stress or lack
f physical training.
Recent data are available from epidemiological studies
nd randomized clinical trials focusing on the prognostic
alue of heart rate. Experimental and clinical evidence
uggests that sustained elevation in heart rate plays a role in
he pathogenesis of atherosclerosis, affecting initiation and
rogression as well as the severity of the disease. Experi-
ental studies demonstrate several vascular responses ac-
ounting for the detrimental effects of accelerated heart rate.
owever, available mechanistic molecular data are surpris-
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Vascular Effects of Heart Rate December 7, 2010:1973–83ingly sparse in the light of the
importance of heart rate for vas-
cular physiology. This article re-
views the effects of heart rate on
vascular homeostasis and hemo-
dynamics that eventually lead to
the phenotype of atherosclerotic
disease.
Epidemiology of
Elevated Heart Rate
In the Framingham study, car-
diovascular and coronary mortal-
ity increased progressively with
resting heart rate in a cohort of
5,070 subjects free from cardio-
ascular disease at the time of entry into the study. The
ffect of heart rate on mortality was independent of tradi-
ional cardiovascular risk factors (9–13). Other studies
onfirm the prognostic importance of resting heart rate for
orbidity and mortality in patients with established coro-
ary artery disease (14,15). The Coronary Artery Surgery
tudy registry assessed the relationship between resting
eart rate and cardiovascular mortality in approximately
5,000 subjects with suspected or proven coronary artery
isease over a median follow-up of 15 years. Multivariate
nalysis revealed that patients with a resting heart rate 83
eats/min had a significantly higher risk of cardiovascular
ortality than subjects with a resting heart rate 62
eats/min (16). Recently, the analysis of a pre-specified
ubgroup of the BEAUTIFUL (morBidity-mortality
vAlUaTion of the If inhibitor ivabradine in patients with
oronary disease and left-ventricULar dysfunction) trial
emonstrated that in patients with coronary heart disease
nd left ventricular systolic dysfunction, a resting heart rate
70 beats/min was associated with an increased cardiovas-
ular mortality as well as increased risk for hospitalization
ue to heart failure, myocardial infarction, or need for
oronary revascularization (17). In subsequent analyses, the
ncreased heart rate was largely associated with coronary
ascular events, but not with heart failure (18,19). The
NTRINSIC RV (Inhibition of Unnecessary RV Pacing
ith AV Search Hysteresis in ICDs) trial followed 1,530
atients after implantation of a dual-chamber implantable
ardioverter-defibrillator and found that intrinsic (unpaced)
eart rate was strongly and independently associated with
he composite end point of heart failure hospitalization and
otal mortality (20). Taken together, there is compelling
pidemiologic evidence that elevated resting heart rate is
redictive of cardiovascular risk, independently of the other
urrently accepted risk factors or characteristics.
athophysiology of Elevated Heart Rate
hear stress and vascular signaling responses. Shear
Abbreviations
and Acronyms
Apo  apolipoprotein
eNOS  endothelial nitric
oxide synthase
FMD  flow-mediated
dilation
I(f)  hyperpolarization-
activated pacemaker
current
NADPH  nicotinamide
adenine dinucleotide
phosphate
VSMC  vascular smooth
muscle celltress is the tangential force in the direction of blood flow, ienerated by flow velocity over the vascular surface and
xpressed in units of force/unit area (dyne/cm2) (for review,
ee Davies [21] and Chatzizisis et al. [22]). Local shear
tress is sensed by endothelial mechanoreceptors, induces
ndothelial gene expression, and thereby determines vascu-
ar phenotypes that promote atherosclerosis susceptibility or
therosclerosis protection. High shear stress promotes adap-
ive vascular dilation (flow-mediated dilation), for example,
y induction of endothelial nitric oxide synthase (eNOS)
ranscription and translation (23). Endothelial cells respond
o variations in shear stress. Vascular regions with oscillating
hear stress and flow reversal correspond with pathologic
hanges in the artery wall and are at risk for atherosclerosis,
hereas sustained laminar flow and high shear stress con-
erve atheroprotective signaling (21,24).
Evidence for a close relation between shear stress and
eart rate originates from in vitro studies that suggest that
hear waveform, and in particular, shear frequency can
nfluence endothelial cell gene expression profiles. Several
tudies compared the impact of steady laminar shear and
realistic” arterial (pulsatile) waveforms on endothelial me-
abolism and report an increased expression of proinflam-
atory, proapoptotic, and procoagulant transcripts (25,26)
nd a reduction of eNOS expression under pulsatile wave-
orms (27). Himburg et al. (28) examined the frequency-
ependent response of aortic endothelial cells to pulsatile
hear stress. A shear frequency of 2 Hz induced a proin-
ammatory phenotype characterized by up-regulation of
onocyte chemoattractant protein-1, intercellular adhesion
olecule-1, and vascular cell adhesion molecule-1, which
as most pronounced under reversing and oscillatory shear.
“physiological” frequency of 1 Hz repressed inflammatory
ranscripts and induced several atheroprotective transcripts
28). In cultured endothelial cells, cyclic stretch was found
o increase the endothelial expression of p22phox, a
embrane-bound subunit of the superoxide-producing nic-
tinamide adenine dinucleotide phosphate (NADPH)-
xidase, which is fundamental for the formation of reactive
xygen species. Endothelial cells treated with inhibitors of
he NADPH-oxidase had reduced superoxide production in
esponse to stretch (29).
Mechanical forces also play an essential role in vascular
mooth muscle cells (VSMC) in the vessel media (30,31). In
ellular models and in vitro studies using VSMC cultured
n deformable substrates, the effect of cyclic strain on
echano- and signal transduction has been investigated,
ncluding altered cell proliferation, alignment, and protein
xpression. Among these, up-regulation of extracellular
atrix proteins (fibronectin [32], collagen [33]), growth
actors (34), and osteogenic markers (35) was linked to a
ascular phenotype characterized by increased stiffness.
oreover, several studies have indicated that cyclic strain
lso amplifies oxidative stress in VSMC. In human coronary
rtery VSMC exposed to pulsatile strain, the observed time-
nd strain-dependent increase in superoxide production was
nhibited by NADPH-oxidase inhibitors but not by xanthine
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December 7, 2010:1973–83 Vascular Effects of Heart Ratexidase or cyclooxygenase inhibitors (36). In cultured vessels,
tretch of 10% and 20% increased generation of reactive oxygen
pecies in contrast to a 5% cyclic stretch (37).
In the context of these results, it could be speculated that
ersons whose arteries are chronically subjected to a partic-
lar range of shear frequencies, such as those with high
esting heart rates, may be at greater risk for atherosclerotic
esion development. However, while the hypothetical asso-
iation between shear stress and heart rate appears to be
lausible, substantial experimental evidence is still lacking.
ndothelial dysfunction and increased heart rate. Be-
ause of its exposed location at the inner vessel wall, the
ndothelial monolayer acts as a mechanosensitive gate-
eeper and a signal transduction interface for hemodynamic
orces. These forces determine the shape and function of
ndothelial cells, allowing the vessel to cope with (patho-)
hysiological conditions (for review, see Berk [24] and
undey [38]). Disturbance of endothelial function is con-
idered a key event in the development of atherosclerosis
nd implies a change from the normally predominant
elease of nitric oxide to that of endothelium-derived
ontracting factors (39,40). Endothelial dysfunction has
een identified as a common consequence of different
ardiovascular risk factors and plays a pivotal role in the
evelopment, progression, and clinical manifestations of
therosclerotic disease (40,41).
To investigate a potential mechanistic link between heart
ate and endothelial function, cholesterol-fed apolipopro-
ein (Apo) E/ mice, a disease model for endothelial
ysfunction, were treated with ivabradine, an inhibitor of
he I(f) channel in the sinoatrial node, which reduced heart
ate by 13.4% and significantly improved endothelial-
ependent vasorelaxation in isolated aortic ring preparations
Fig. 1). The improvement of endothelial function was
ndependent of blood pressure or lipid levels (42). Experi-
ents by Drouin et al. (43) add to these findings, showing
hat in dyslipidemic mice expressing the human ApoB-100,
eart rate reduction with ivabradine prevented endothelial
ysfunction in renal and cerebral arteries. Similarly, phar-
acological reduction of heart rate improved endothelial
unction in isolated corpora cavernosa, where endothelial
ell function determines erectile capacity. The treatment
as effective both as prevention as well as treatment of
rectile dysfunction (44). Taken together, these studies in
ifferent mouse models and different vascular beds consis-
ently show that mild heart rate reduction (13% to 17%)
rotects endothelial-dependent vasorelaxation. In the study
y Drouin et al. (43), the impairment of acetylcholine-
nduced, endothelium-dependent vasodilation of cerebral
nd renal arteries was restored by ivabradine, but not by
etoprolol dosed to equally reduce heart rate. Therefore, it
ppears possible that ivabradine may exert vasoprotective
ffects in addition to heart rate reduction; however, this is a
uestion of ongoing research (45).
An increased formation and/or release of reactive oxygenpecies appears to be a common denominator underlying pndothelial dysfunction and is 1 of the key events in the
athogenesis of atherosclerosis (46). Indeed, ivabradine-
nduced heart rate reduction in ApoE/ mice was associ-
ted with inhibition of NADPH-oxidase activity and su-
eroxide release. In addition, vascular lipid peroxidation as a
lobal marker of oxidative stress was decreased (42). The
entral characteristic of a dysfunctional endothelium is a
educed availability of NO. Restoration of impaired endo-
helial function by pharmacological interventions (e.g., st-
tins) is associated with a restoration of endothelial NO
roduction (47,48). However, aortic tissue of ApoE/
ice treated with ivabradine did not exhibit a significant
p-regulation of eNOS expression (42). In contrast, ivabra-
ine treatment up-regulated eNOS expression in the cor-
Figure 1 Endothelial Function of Wild Type and ApoE/ Mice
In wild type (WT) mice (squares) and in apolipoprotein (Apo) E/ mice after 6
weeks of treatment with cholesterol-rich diet with ivabradine (Iva), 10 mg/kg/
day (down-pointing triangles) or vehicle treatment (up-pointing triangles), aor-
tic segments were isolated, and their functional performance was assessed
in organ chamber experiments. Heart rate reduction improved endothelium-
dependent vasodilation induced by carbachol (A). Endothelium-independent
vasorelaxation induced by glyceroltrinitrate was similar in all groups (B). Both
were expressed as percent of maximal phenylephrine-induced vasoconstriction.
Mean  SEM, n  10 per group. p  0.05 versus ApoE vehicle. Adapted
from Custodis et al. (42).ora cavernosa of ApoE/ mice (44). Even though a direct
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Vascular Effects of Heart Rate December 7, 2010:1973–83nvolvement of eNOS was not reported, Drouin et al. (43)
howed in dyslipidemic mice that vasodilation of renal
rteries induced by acetylcholine was sensitive to eNOS
nhibition by Nnitro-L-arginine, indicating at least a
artial contribution of NO to ivabradine-induced improve-
ent of endothelial function. Recchia et al. (49) also found
significant decrease of cardiac NO production after 3
eeks of rapid pacing in dogs with pacing-induced heart
ailure.
The clinical data on endothelial function affected by heart
ate are not yet conclusive. In a large cohort of Framingham
tudy participants, heart rate was positively associated with
rachial artery flow-mediated dilation (FMD) (50). Several
tudies that explicitly looked at heart rate and FMD showed
n inverse relation between heart rate and FMD but are
everely limited by the small number of subjects examined
51–54). Therefore, prospective clinical studies to determine
he role of resting heart rate in FMD and to test the effect
f randomized heart rate reduction on FMD are needed.
Increased levels of circulating markers of inflammation
uch as high-sensitivity C-reactive protein are associated
ith endothelial dysfunction and future cardiovascular risk
55). Two population-based studies reported a positive
orrelation between increased resting heart rate and markers
f inflammation (C-reactive protein, white blood cell count,
nd fibrinogen) in apparently healthy subjects (56,57).
hus, increased heart rate may contribute to endothelial
ysfunction by up-regulation of inflammatory cytokines.
icroalbuminuria is a marker of generalized endothelial
njury and correlates with renal and cardiovascular end organ
amage (58,59). In a recent analysis of the I-SEARCH (The
nternational Survey Evaluating Microalbuminuria Routinely
y Cardiologists in Patients with Hypertension) study, an
bservational study in hypertensive patients, heart rate was a
trong predictor for the prevalence of microalbuminuria, even
fter adjustment for hypertension and risk factors such as
re-existing cardiac disease, diabetes mellitus, age, and sex
60,61). In summary, the data show an association of heart rate
ith circulating markers of vascular inflammation; however,
he underlying molecular mechanisms are not known.
ascular structure and increased heart rate. Blood vessels
dapt to mechanical demands and remodel by changing
heir geometry, structure, and elastic properties. Compli-
nce, defined as change in volume (dV) for a given change
n distending pressure (dP), or dV/dP, decreases steadily
ith vascular aging (62). Aortic stiffness, namely, the
nverse of compliance, predicts cardiovascular morbidity and
ortality in patients with essential hypertension, end-stage
enal failure, or diabetes mellitus (63,64). Experimental
vidence for a link between arterial compliance and heart
ate was presented by Mangoni et al. (65), who demon-
trated that progressive increases in heart rate caused by
trial pacing in rats led to marked reductions in carotid
rtery compliance. The stiffening effect of tachycardia
as shown to be independent of sympathetic tone (66).
a Cunha et al. (67) found a significant positive link detween high heart rate and arterial stiffness measured at the
ite of central and lower limb arteries by pulse wave velocity
easurements and high-resolution echo tracking. These
ndings are in line with a study of Giannattasio et al. (68),
ho showed that radial and carotid artery distensibility (an
ndex of arterial stiffness measured by vascular echo track-
ng) was decreased during pacing-induced increase of heart
ate. In treated hypertensive patients, high heart rate was
ssociated with an accelerated progression of arterial stiff-
ess, as estimated by carotid/femoral pulse wave velocity
69). Other investigations report opposite heart rate-
nduced effects on vascular wall mechanics. Wilkinson et al.
70) used pulse wave analysis to calculate an augmentation
ndex as a measure of pressure wave reflection that accounts
or arterial stiffness in patients with permanent cardiac
acemakers. Incremental pacing led to a linear reduction in
he augmentation index and revealed an inverse relationship
etween heart rate and systemic arterial stiffness (70).
imilar results are reported by an earlier study showing
ncreased aortic distensibility, measured invasively by aortic
ressure recordings, by pacing induced increases in pulse
ate (71). Apparently, differences may evoke from different
ethods (ultrasonic echo tracking vs. pulse wave analysis)
nd parameters (arterial distensibility vs. augmentation in-
ex) that were applied. What is noticeable is that the
ajority of studies reporting a positive association between
eart rate and vascular stiffness applied direct measurements
f vascular compliance (e.g., by echo tracking) rather than
ulse wave velocity or augmentation index.
At least, the reported observations suggest synergistic
ffects of heart rate and arterial blood pressure on the
asculature and the progression of atherosclerotic disease.
redominantly at the sites of atherosclerosis-prone areas,
echanical stress may result in pathological alterations and
ven vascular “fatigue.” The concept of cumulative vascular
njury caused by fatigue was introduced by Thubrikar and
obicsek (72) and describes a phenomenon deduced from
onbiological materials that occurs in vessels exposed to
ulsatile pressure. At sites of stress concentration (e.g.,
ascular orifices), an accelerated heart rate potentiates the
patial mechanic load—defined by blood pressure—and
ccelerates vascular injury. Such a hypothesis was taken into
ccount by Bassiouny et al. (73), who used a rate-pressure
roduct (mean blood pressure  mean heart rate) to
uantify hemodynamic load in cynomolgus monkeys and
eported a positive relationship between hemodynamic
tress and the extent of atherosclerotic lesions in the
nfrarenal aorta. Mechanistically, again, there is likely a
isturbed endothelial-dependent vasorelaxation (74,75).
Heart rate reduction by I(f)-channel inhibition in spon-
aneously hypertensive rats reduced heart rate by as much as
0%, mediated antihypertrophic effects in terms of reduc-
ion of medial cross-sectional area in the thoracic aorta, and
educed wall stress (76). However, whereas chronic ivabra-
ine treatment attenuated maladaptive alterations, an acute
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December 7, 2010:1973–83 Vascular Effects of Heart Rateharmacological intervention by repetitive intravenous bo-
uses of ivabradine did not affect arterial stiffness (77).
The finding that the augmentation index is influenced by
eart rate is supported by population data from a cross-
ectional study (78) and recent data from the CAFE
Conduit Artery Function Evaluation) study (79,80). The
ajor finding of the CAFE study was that the beta-blocker
tenolol was less effective than amlodipine in lowering
entral aortic systolic pressures, despite similar control of
rachial blood pressure. The CAFE heart rate study focused
n the importance of heart rate as a determinant of this
ffect and showed that a lower heart rate induced by
eta-blockade was associated with higher aortic systolic
ressure and pulse pressure, an effect that was primarily
ttributed to increased central pressure wave reflections at
ower heart rates (Fig. 2) (81). As possible mechanisms that
ccount for the inverse relationship between heart rate and
ortic pressure, the authors discuss an increase of central
ystolic pressure attributable to a shift of the reflected wave
nto late systole due to the reduction in ejection duration by
eart rate reduction, and an increased stroke volume sec-
ndary to heart rate reduction and better diastolic filling
Frank-Starling mechanism), which is then ejected into the
roximal aorta with its windkessel function. Furthermore,
he vasoconstrictor effects of beta-blockers on the peripheral
irculation that increase pulse wave reflection have to be
onsidered. The CAFE heart rate analysis adds relevant
ndings as it represents the first clinical trial assessing
emodynamic effects of a pharmacological heart rate reduc-
ion in a large number of patients. In the light of the CAFE
tudy data, the net clinical effect of a beta-blocker–induced
eart rate reduction in hypertensions remains controversial.
therosclerosis and increased heart rate. Pioneering ex-
eriments were conducted by Beere et al. (82,83), who
stablished the first evidence for a direct connection be-
ween heart rate and lipid-induced atherogenesis in cyno-
olgus monkeys with reduced heart rate after ablation of
he sinoatrial node, which exhibited reduced coronary and
arotid atherosclerosis compared with sham-operated litter-
ates. Subsequently, Kaplan et al. (84) demonstrated that
aturally occurring differences in casual heart rate in mon-
eys were related to coronary atherosclerosis; monkeys with
igh heart rate exhibited atherosclerotic lesions more than
wice as extensively as low heart rate littermates. In another
tudy, the same authors reported a significant association
etween the extent of heart rate response to psychological
tress and the degree of coronary atherosclerosis in the same
pecies (85). Korshunov and Berk (86) characterized carotid
utward remodeling and intima-media thickening in differ-
nt inbred mouse strains. Vascular remodeling was highly
ependent on genetic determinants and hemodynamic fac-
ors (86). Among these, heart rate, but not systolic blood
ressure, was predictive for increased intima-media thick-
ning. Recent data in ApoE/ mice established that heart
ate reduction by ivabradine decreased atherosclerotic tlaque size in the aortic root and in the ascending aorta (42).
vabradine prevented atherogenesis when given simulta-
eously with a high cholesterol diet but also was effective to
educe plaques size when given to animals 4 weeks after
nitiation of a high-cholesterol diet (44). In this model,
harmacological heart rate reduction led to a reduction of
Figure 2 Changes of Vascular Physiology
in Response to Heart Rate Reduction
Heart rate reduction increases central systolic blood pressure (SBP) augmenta-
tion for an identical pulse height of the forward-ejected pressure wave and the
same reflected pressure wave. ED  ejection duration; T0  onset of the
forward-ejected wave; Tr  time to return at the aorta of the backward-reflected
wave from T0. Adapted from Safar et al. (81).he vascular expression of monocyte chemoattractant
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Vascular Effects of Heart Rate December 7, 2010:1973–83rotein-1. Monocyte chemoattractant protein-1 has been
hown to be regulated by hemodynamic properties such as
hear stress and cyclic strain (up-regulated by proatheroscle-
otic shear patterns) (87,88). While animal studies provide
rowing mechanistic evidence for the link between heart
ate and an atherosclerotic phenotype, clinical data are
imited. Perski et al. (89,90) studied the progression of
oronary artery lesions in men who survived a myocardial
nfarction before the age of 45 years and reported a
ignificant correlation between heart rate and the severity
nd progression of coronary atherosclerosis.
The contribution of heart rate reduction to the clinical
ffects of beta-blockers and calcium-channel blockers has
een analyzed in several studies. A meta-regression analysis
f 25 randomized clinical trials (21 with beta-blockers and
with calcium-channel blockers; n  30,904 patients)
erformed by Cucherat (91) suggests that the beneficial
ffect of beta-blockers and calcium-channel blockers in
ost-myocardial infarction patients is proportionally related
o the reduction of resting heart rate. Sipahi et al. (92)
ecently reported a post-hoc analysis of data from 4 intra-
ascular ultrasonography studies showing that beta-blocker
reatment is associated with a reduction of the progression
f coronary atherosclerosis. The beta-blocker group showed
heart rate reduction by 2.7 beats/min (4%) but no
ifference in blood pressures compared with placebo (92).
he association of beta-blockers with a reduced progression
ate remained statistically significant after adjustment for
verage heart rates during treatment. The investigators
uggest that reduced heart rate may not be the only
echanism responsible for the beneficial effects of beta-
lockers on atherosclerosis and propose that reduced affinity
f low-density lipoprotein cholesterol to vessel wall proteo-
lycans and blunting of the catecholamine-induced in-
reases in endothelial permeability to lipoproteins may be
lternative mechanisms of action. Bangalore et al. (93)
nalyzed 9 randomized studies evaluating beta-blockers for
ypertension. In contrast to the findings in patients with
yocardial infarction or heart failure, the meta-analysis
ound that beta-blocker–associated reduction in heart rate
ncreased the risk of cardiovascular events and death for
ypertensive patients. This analysis is driven by atenolol,
hich was used as beta-blocker in 78% of patients and has
n inferior hemodynamic and metabolic profile compared
eta-blockers with vasodilating properties. However, the
xisting data do not provide evidence for a beneficial effect
f heart rate reduction using beta-blockers. In addition to
he limitations of the retrospective clinical analyses of this
uestion, the importance of heart rate reduction is difficult
o interpret because of the very significant vascular effects of
hese drugs in addition to their impact on heart rate.
lthough beta-blocker treatment was reported to exert
ntiatherosclerotic effects in different species (for review, see
aplan and Manuck [94] and Bondjers [95]), the molecular
echanisms were not studied, and possible negative effectsf comparators such as hydralazine are not excluded (96). pherefore, to assess the importance of a pharmacological
eart rate reduction for the prevention of atherosclerosis
rogression in patients with coronary heart disease, a pro-
pective clinical trial with an I(f) inhibitor, for example,
sing intravascular ultrasonography may be an important
ext step.
eart rate and myocardial oxygen supply. In the coronary
rteries, blood flow is determined by the pressure gradient
etween the diastolic pressure in the aortic root, the right
trial pressure, and the duration of the diastole (1). Both the
riving pressure gradient and the duration of diastole are
ntegrated into the diastolic pressure-time integral reflecting
he driving force for coronary blood flow. Due to its
echanical determinants, largely the phasically-contracting
yocardium, coronary blood flow is pulsatile and occurs
ostly during diastole (1). Increases in heart rate are
ssociated with over-proportionate decreases in diastolic
uration and, as a consequence, coronary perfusion and
yocardial oxygen supply are reduced. Increases in coronary
lood flow through metabolic coronary vasodilation in
ormal, nonstenotic coronary arteries act in concert with the
eduction of blood flow in post-stenotic myocardium, sec-
ndary to abbreviated diastolic duration; in consequence,
he driving gradient for collateral blood flow is reduced, and
marked reduction in post-stenotic blood flow ensues
Fig. 3) (1). Conversely, reduction of heart rate favorably
edistributes myocardial blood flow toward the ischemic
egion (97) and finally reduces also infarct size (98,99).
linically, precipitation of myocardial ischemia becomes
minent in diseased coronary arteries, where an increase in
eart rate may lead to angina and myocardial ischemia
100–102).
eart rate and coronary plaque instability. The charac-
eristics of coronary shear stress are determined by the pulsatile
ature of coronary flow. Shear stress attains a low and oscilla-
ory pattern during systole followed by a diastolic increase to a
iastolic maximum (103,104). In regions of low shear stress,
rogressive atherosclerosis and outward remodeling develop
105). Although an experimental and definite verification is
acking and a direct effect of heart rate on shear stress has not
een investigated, one could speculate that as a consequence of
shorter diastole in regions susceptible to atherosclerosis,
rotective diastolic shear stress is reduced, resulting in longer
eriods of systolic shear stress.
In a retrospective analysis, Heidland et al. (106) investi-
ated data from 106 patients who underwent subsequent
oronary angiographies within 6 months. They analyzed 53
atients with initially smooth stenotic lesions in which
laque disruption developed by the time of the second
oronary angiogram, and compared these patients with
atched subjects exhibiting smooth stenoses without an-
iographic signs of plaque disruption. Logistic regression
nalysis identified positive associations between plaque dis-
uption and a mean heart rate80 beats/min and a negative
ssociation with the use of beta-blockers (106). This im-
ortant clinical finding may be at least partially explained by
a
c
m
n
a
s
t
a
a
m
p
r
f
a
f
l
p
t
C
p
q
d
V
a
c
T
p
b
e
1
g
b
o
i
o
t
o
A
s
r
o
v
C
1979JACC Vol. 56, No. 24, 2010 Custodis et al.
December 7, 2010:1973–83 Vascular Effects of Heart Ratedynamic coronary geometry and alternating dynamic
hanges imposed on the vessel during the cardiac cycle that
ay contribute to the initiation and development of coro-
ary atherosclerosis (107). The motion of the coronary
rteries during the cardiac cycle—primarily of the epicardial
egments—is characterized by phasic bending of the curva-
ures and periodically changing torsion of the vessel directly
ffecting hemodynamic properties (107). Yang et al. (108)
pplied computational MRI-based models to characterize
echanical stress imposed on coronary atherosclerotic
laques and identified cyclic bending as a relevant stressor in
upture-prone areas. Other types of mechanical stress af-
ecting plaque morphology are circumferential wall stress
nd repetitive tensile stress, which have been shown to
acilitate and to trigger coronary plaque rupture (109). At
east tensile stress was shown to stimulate matrix metallo-
roteinase-1—a key player in extracellular matrix degrada-
ion and plaque rupture—in coronary artery lesions (110).
onsistently, hemodynamic factors that may precipitate
laque disruption are characterized by pulsatility and fre-
uency of mechanical stress and are at least defined by the
Figure 3 Change in Driving Pressure Gradient for Collateral Blo
Schematic representation of changes in the driving pressure gradient for collatera
stenotic myocardium (right). There is an autoregulatory decrease in microvascular
vasodilation and a decrease of microvascular resistance occur in healthy myocard
stenotic myocardium, no further dilation is possible, and the reduction in diastolic
fice of collaterals into the post-stenotic coronary vasculature are increased. Periphuration/length of the cardiac cycle. (ascular growth and increased heart rate. Angiogenesis
nd arteriogenesis are natural defense mechanisms to
ompensate for arterial stenosis or occlusion (97,111).
hus, stimulating vascular growth is a promising thera-
eutic goal in arterial occlusive disease (112,113). Using
radycardic pacing in a rabbit model, a proangiogenic
ffect of heart rate reduction was described as early as
981 (114). More recently, enhanced vascular endothelial
rowth factor expression was shown to be critical in
radycardia-induced angiogenesis (115). Up-regulation
f vascular endothelial growth factor is thought to be
nduced by cardiac myocyte stretch (116). In a dog model
f gradual coronary occlusion, bradycardia increased ar-
eriogenesis, which was accompanied by an up-regulation
f Tie-2 and vascular endothelial growth factor (117).
gain, longer duration of diastole with increased shear
tress as well as myocardial stretch are discussed as
esponsible mechanisms. However, no data on the effects
f bradycardia and reduced pulse pressure frequency on
ascular growth in the peripheral circulation are available.
ollateral artery growth is a NO-dependent process
ow and Microvascular Resistance
flow and of microvascular resistance in normal myocardium (left) and in post-
ance of the post-stenotic myocardium. With increasing heart rate, metabolic
sulting in decreased pressure at the origin of collaterals. In contrast, in post-
on prevails; subsequently, microvascular resistance and the pressure at the ori-
ripheral. Adapted from Heusch (1).od Fl
l blood
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he noncoronary vascular bed.
onclusions and Perspective
eart rate has emerged as an independent risk factor both
n primary prevention and in patients with hypertension,
oronary artery disease, and myocardial infarction (Fig. 4)
119–126). Available data support a strong association
etween elevated heart rate and negative cardiovascular
ffects. Increased heart rate impairs endothelial function in
nimal models and may contribute to reduced shear stress
nd vascular compliance. Heart rate reduction by sinus node
blation or pharmacological intervention by I(f)-channel
nhibition reduces the formation of atherosclerotic plaques
n animal models of lipid-induced atherosclerosis. By pro-
onging diastole and improving endothelial function, re-
uced heart rate stimulates vascular growth. While these
xperimental data provide considerable descriptive evidence
f the pathophysiological concept, the current mechanistic
nderstanding of the underlying molecular mechanisms war-
Figure 4 Heart Rate as a Cardiovascular Risk Factor and Vasc
(Top) Clinical evidence for the potential role of heart rate as a cardiovascular risk
disease. (Bottom) Evidence for vascular effects of heart rate reduction from animants further investigation. However, prospective clinical evi-ence regarding the effects of heart rate reduction on cardio-
ascular events is lacking. Importantly, transition from
xperimental results to clinical evidence has to be further
stablished, particularly to clarify whether pharmacological
eart rate reduction might be beneficial for the prevention of
therosclerotic disease. Ongoing clinical trials and registries
ill further consider the role of heart rate and heart rate
eduction in patients with coronary artery disease (127–129).
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